Virtus Health Limited

Income statement

Notes on the income statement:

FY2018 figures are derived: Revenue is back-calculated from FY2019's disclosed +6.1% growth. EBITDA is back-calculated from FY2019's disclosed −2.3% decline.

FY2017 EBITDA: is before impairment, per the company's definition.

FY2020 EBITDA conflict: Kalkine reports FY2020 reported EBITDA of A$46.2m. Kalkine also cites an FY2020 EBITDA margin of 21.5%, which implies about A$55.7m. The A$58.3m adjusted figure is derived from the disclosed +44.2% FY2021 adjusted EBITDA growth.

FY2021 NPAT conflict: Reported NPAT is A$43.1m (MarketIndex: A$43.135m). A separate Kalkine note cites A$43.8m.

FY2021 adjusted EBITDA margin conflict: Kalkine cites 25.1%, but A$84.1m ÷ A$324.6m computes to 25.9%.

FY2020 dividend: Only the interim 12c was paid (April 2020); the final dividend was nil.

FY2021 dividends: Interim 12c plus final 12c, both fully franked.

Revenue CAGR FY2017–FY2021: (derived): about 6.1% per year.

Half-year detail

Source: H1 FY21 ASX announcement (16 Feb 2021); Kalkine. The 2.8x H1FY20 figure is described as gearing to adjusted group EBITDA.

Balance sheet

Notes:

• The FY2020 leverage of 2.1x is per the company (H1FY21 announcement).

• Debt repayments exceeded A$20m between March 2020 and December 2020.

• The A$35m placement in August 2021 (post FY2021 balance date) further reduced leverage.

• Under BGH ownership the capital structure has been re-levered through acquisition financing. Terms are not publicly disclosed.

Cash flow

Source: Kalkine summary of the FY2021 Appendix 4E. No buybacks were disclosed.

Trend commentary

FY2017–FY2019: stagnation and mix pressure. Revenue grew slowly, with FY2017 down 1.8%. EBITDA slipped from A$64.8m to A$63.5m and Australian margins compressed from 30.7% to 28.0%. Management attributed this to four factors:

• lower genetic testing volumes;

• higher compliance costs in diagnostics;

• relocation and upgrade costs at the Alexandria and Hobart day hospitals;

• a mix shift towards low-cost IVF.

International acquisitions (Trianglen, Complete Fertility) and QFG full-service growth carried top-line growth. Danish revenue was volatile: DKK13.4m in FY2019 versus DKK20.9m in FY2018 for one clinic cohort.

FY2020: COVID shock. The government-mandated suspension of elective IVF in late March and April 2020 cut revenue 7.6%. Reported NPAT fell to almost nil (A$0.5m) after impairments and abnormal items; NPAT before abnormals was about A$25.9m per MarketIndex. The final dividend was cancelled. AASB 16 inflated EBITDA comparatives from FY2020 onward.

FY2021: inflection. Pent-up demand produced record revenue of A$324.6m (+25.4%). Reported EBITDA reached A$93.4m, flattered by JobKeeper. On the company's adjusted measure, EBITDA was A$84.1m (+44.2%) and NPAT A$37.0m. Three things drove the recovery:

• IVF behaved as a non-discretionary service;

• operating leverage at clinics and day hospitals;

• PGT growth.

International EBITDA rose 68.1%. Leverage fell to 1.7x, which set up the A$35m growth placement and, ultimately, the private-equity contest.

FY2022 onward: not publicly reported. Q1 FY22 group and ARS revenue were each up 1.5% on the prior year, and diagnostics up 10.4%. After that, Virtus financials went dark.

Read-across from Monash IVF suggests the domestic market has softened since FY2025. Monash's FY26 results cited a 4.7% decline in national stimulated cycle volumes on a rolling basis to April 2026. That implies volume pressure on Virtus's core ARS profit pool in FY2026.

Guidance and consensus

There is no management guidance and no analyst consensus, because the company is private. The best proxies are peer commentary and regulator data. Monash IVF expects a stronger FY27 as market conditions improve, after a 4.7% contraction in national stimulated cycles in 2026.

Bull case

1. Scale moat strengthened by regulation. National ACSQHC accreditation and mandatory outcome reporting raise fixed compliance costs that the roughly 37%-share leader can amortise best, accelerating consolidation of independents. Concept Fertility is the template.

2. Higher-value services per patient. Diagnostics grew 12.8% and day hospitals 41.4% in FY2021. Combined with genomics (A$3m grant) and Fertilo, revenue per patient can rise even if cycle counts are flat.

3. Structural demand. Later parenthood, egg freezing and diverse family formation sustain long-run demand. FY2021 proved IVF behaves as non-discretionary, with revenue up 25% after the shutdown.

Bear case

1. Volume and margin squeeze. The national cycle decline and Monash's 41% drop in underlying NPAT signal sector-wide operating deleverage, which would hurt a leveraged PE-owned platform more.

2. Safety and reputation tail risk. The QFG donor sperm revelations (2025) could trigger claims, regulatory conditions and patient attrition, as the Monash class action precedent shows.

3. Exit constraints. ACCC sensitivity limits domestic bolt-ons. Listed sector valuations (Monash under A$1/share) may compress BGH's exit multiple relative to the about 16–19x P/E paid in 2022.

Catalysts and monitorables (next 12 months)

• Phase-one national ART accreditation milestones (target January 2027) and passage of Victoria's 2026 Bill.

• Medicare stimulated-cycle data, as a monthly volume proxy.

• Any legal action or regulator response linked to QFG donor programs.

• Concept Fertility integration and further bolt-ons (WA, SA, NT gaps).

• BGH exit signals: banker mandates, IPO-readiness, secondary sale.

• Competitor M&A (WHSP/Genesis versus Monash; Genea, City Fertility ownership changes).

• Status of international assets (retention versus divestment).

Analyst verdict

Virtus Health remains the anchor asset of Australian fertility care. It has the largest share of a consolidated market (about 37%), a full stack of clinics, laboratories, genetics and day hospitals, and a brand portfolio covering premium and low-cost tiers.

Its last public financials, from FY2021, showed a business capable of strong operating leverage: adjusted EBITDA of A$84.1m on A$324.6m revenue, with leverage cut to 1.7x. BGH Capital won a bruising auction against CapVest by paying A$8.155 per share, about 15% above its own opening indication. It has since run the playbook it described: steady management under CEO James Pyne since late 2023, investment in AI and genomics, and a national bolt-on (Concept Fertility, July 2026) that gives Virtus a truly national network of more than 50 clinics.

The investment debate has shifted since the take-private. The sector moved from a post-COVID boom to a 2025–26 down-cycle in volumes, with national stimulated cycles falling and the listed peer's profit dropping 41%. At the same time, a series of laboratory-safety failures, including Virtus's own QFG donor sperm revelations, triggered the most significant regulatory overhaul in the industry's history.

For a scaled operator these forces cut both ways. Compliance costs and reputational risk rise, but so do barriers to entry and the pressure on independents to sell.

Our assessment is that Virtus's franchise value is intact and probably enhanced relative to sub-scale rivals. Near-term earnings, however, are likely below the FY2021 peak in margin terms, and there is a meaningful legal and reputational tail.

The key monitorables are volume recovery, governance remediation in donor programs, and the shape of BGH's eventual exit. A sale to a strategic or infrastructure-style health investor looks more plausible than an IPO, given depressed listed peer valuations.

Overall characterisation: structurally advantaged and cyclically challenged, with execution on safety governance as the swing factor.